diethyl 3-pyridylcyanomethyl phosphonate | 117504-12-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: diethyl 3-pyridylcyanomethyl phosphonate
• 英文别名: Diethyl [cyano(pyridin-3-yl)methyl]phosphonate；2-diethoxyphosphoryl-2-pyridin-3-ylacetonitrile
• CAS: 117504-12-8
• 化学式: C₁₁H₁₅N₂O₃P
• 分子量: 254.225
• InChiKey: RQTAHFCMXLURHX-UHFFFAOYSA-N

物化性质

• 沸点：
  159-160 °C
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  72.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl 3-pyridylcyanomethyl phosphonate 在 盐酸 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 (E)-3-[3-(3-Amino-5-ethyl-6-methyl-2-oxo-1,2-dihydro-pyridine-4-carbonyl)-phenyl]-2-pyridin-3-yl-acrylonitrile
  参考文献：
  名称：

  4-Benzyl- and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones, a New Family of Potent Anti-HIV Agents:  Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains

  摘要：

  The 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 13 and 14 are representatives of a new class of highly potent non nucleoside type inhibitors of HIV-1 reverse transcriptase. To conduct SAR studies on these two lead compounds, 102 new analogues were prepared. Thirty-three compounds displayed nanomolar range activity in vitro against wild-type HIV-1, and among these, 18 were active against the 103N, Y181C, and Y188L mutant strains with IC50 values inferior to 1 muM. Evaluation of this group of analogues against an additional eight single [100I, 101E, 106A, 138K, 179E, 190A, 190S, 227C] and four double HIV mutant strains [100I + 103N, 101E + 103N, 103N + 181C, and 227L + 106A], which are often present in HIV infected patients, permitted the selection of eight compounds, 17x, 18b, 18c, 18f, 18g, 27, 30, and 42, which are globally more active than the lead molecules 13/14, emivirine and the currently used NNRTI, nevirapine. Further comparison of the 3'-CN-substituted benzoylpyridinone compound 18c, and the corresponding 3'-acrylonitrile-substituted analogue 30, to efavirenz, the reference molecule in anti-HIV therapy today, revealed that the pyridinone analogues displayed a superior inhibition profile in the in vitro cellular assay system. These results form a solid basis for continued optimization of the pyridinone series.

  DOI：

  10.1021/jm0407658
• 作为产物：
  描述：

  3-溴吡啶 、 氰甲基磷酸二乙酯 在 四(三苯基膦)钯 sodium hydride 作用下， 以 乙二醇二甲醚 为溶剂， 反应 3.0h， 以79%的产率得到diethyl 3-pyridylcyanomethyl phosphonate
  参考文献：
  名称：

  Palladium-catalyzed condensation of aryl halides with phenylsulfonylacetonitrile and diethyl cyanomethylphosphonate.

  摘要：

  用钯(0)催化的芳香卤化物与苯基磺酰乙腈和二乙基氰基甲基膦酸钠在二甲氧基乙烷中缩合，得到相应的α-苯基磺酰芳烃乙腈和二乙基芳氰基甲基膦酸酯，产率良好。α-苯基磺酰芳烃乙腈可以用锌轻松去磺化生成芳烃乙腈，而芳氰基甲基膦酸酯通过霍纳-艾蒙斯反应转化为烷基亚烯芳烃乙腈。

  DOI：

  10.1248/cpb.38.1513

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• Sakamoto, Takao; Katoh, Eisaku; Kondo, Yoshinori, Heterocycles, 1988, vol. 27, # 6, p. 1353 - 1356
  作者：Sakamoto, Takao、Katoh, Eisaku、Kondo, Yoshinori、Yamanaka, Hiroshi

  DOI：——

  日期：——
• SAKAMOTO, TAKAO;KATOH, EISAKU;KONDO, YOSHINORI;YAMANAKA, HIROSHI, CHEM. AND PHARM. BULL., 38,(1990) N, C. 1513-1517
  作者：SAKAMOTO, TAKAO、KATOH, EISAKU、KONDO, YOSHINORI、YAMANAKA, HIROSHI

  DOI：——

  日期：——
• SAKAMOTO, TAKAO;KATOH, EISAKU;KONDO, YOSHINORI;YAMANAKA, HIROSHI, HETEROCYCLES, 27,(1988) N 6, C. 1353-1356
  作者：SAKAMOTO, TAKAO、KATOH, EISAKU、KONDO, YOSHINORI、YAMANAKA, HIROSHI

  DOI：——

  日期：——
• 4-Benzyl- and 4-Benzoyl-3-dimethylaminopyridin-2(1<i>H</i>)-ones, a New Family of Potent Anti-HIV Agents:  Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains
  作者：Abdellah Benjahad、Karine Courté、Jérôme Guillemont、Dominique Mabire、Sophie Coupa、Alain Poncelet、Imre Csoka、Koen Andries、Rudi Pauwels、Marie-Pierre de Béthune、Claude Monneret、Emile Bisagni、Chi Hung Nguyen、David S. Grierson

  DOI：10.1021/jm0407658

  日期：2004.10.1

  The 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 13 and 14 are representatives of a new class of highly potent non nucleoside type inhibitors of HIV-1 reverse transcriptase. To conduct SAR studies on these two lead compounds, 102 new analogues were prepared. Thirty-three compounds displayed nanomolar range activity in vitro against wild-type HIV-1, and among these, 18 were active against the 103N, Y181C, and Y188L mutant strains with IC50 values inferior to 1 muM. Evaluation of this group of analogues against an additional eight single [100I, 101E, 106A, 138K, 179E, 190A, 190S, 227C] and four double HIV mutant strains [100I + 103N, 101E + 103N, 103N + 181C, and 227L + 106A], which are often present in HIV infected patients, permitted the selection of eight compounds, 17x, 18b, 18c, 18f, 18g, 27, 30, and 42, which are globally more active than the lead molecules 13/14, emivirine and the currently used NNRTI, nevirapine. Further comparison of the 3'-CN-substituted benzoylpyridinone compound 18c, and the corresponding 3'-acrylonitrile-substituted analogue 30, to efavirenz, the reference molecule in anti-HIV therapy today, revealed that the pyridinone analogues displayed a superior inhibition profile in the in vitro cellular assay system. These results form a solid basis for continued optimization of the pyridinone series.